Differential T-cell profiles determined by Hepatitis B surface antigen decrease among people with Human Immunodeficiency Virus /Hepatitis B Virus coinfection on treatment.

BACKGROUND

Several studies have reported that combination antiretroviral therapy (cART) enhances the hepatitis B surface antigen (HBsAg) clearance rate in Human Immunodeficiency Virus-1/Hepatitis B Virus (HIV/HBV) coinfected patients, yet the associated immunological characteristics remain unclear.

METHODS

Global and specific immune phenotypic profiles were examined in 48 patients with HIV/HBV coinfection before cART and at 1-year, and 3-year after cART using flow cytometry. In addition, 61 patients with HBV monoinfection were included for comparison.

RESULTS

HBsAg response (sAg-R) was defined as > 0.5 log decrease within six months of cART initiation, and 16 patients achieved it. Patients with sAg-R (the sAg-R group) exhibited distinct immune phenotypes compared to those of HBsAg-retained patients (the sAg-NR group). Notably, patients with sAg-R had lower CD4 T cell counts and a higher number of HBcAg-specific T cells. Further, the sAg-R group exhibited upregulation of HLA-DR, Ki67, and PD-1 in CD4 T cells and heightened HLA-DR and T-bet in CD8 T cells. However, the sAg-R group had fewer TEMRA cells but more TEM and Th17 cells than those in the sAg-NR group. Expression of various markers, including HLA-DRCD4, Ki67CD4, PD-1CD4, CD38CD8, HLA-DRCD8, TIM-3CD8, HBV-specific CD4 T cell secreting IFN-γ and IL-2, and specific CD8 T cell secreting IFN-γ and IL-2, correlated with HBsAg decrease.

CONCLUSION

The decline in HBsAg levels during cART in HIV/HBV coinfection involves significant alterations in CD4 and CD8 T cells phenotypes, offering a novel perspective on a functional HBV cure.